Amneal Pharmaceuticals, Inc. (AMRX) stock
AMRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 10/3072% above fair value
$21.88+0.76 (+3.60%)
Close on Nov 18, 2026Market cap $6.99BP/E 44.7Yield –
Amneal Pharmaceuticals free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Amneal Pharmaceuticals's free cash flow for the twelve months ending Jun 30, 2026 was $127.84M, down 54.8% year over year. For fiscal 2025 it was $269.93M, up 11.0% from the year before. The highest annual figure on record is $322.56M in fiscal 2020.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $269.93M | +11.0% |
| FY2024 | Dec 31, 2024 | $243.18M | -19.6% |
| FY2023 | Dec 31, 2023 | $302.36M | +1517.5% |
| FY2022 | Dec 31, 2022 | $18.69M | -90.4% |
| FY2021 | Dec 31, 2021 | $194.09M | -39.8% |
| FY2020 | Dec 31, 2020 | $322.56M | – |
| FY2019 | Dec 31, 2019 | -$45.48M | -127.2% |
| FY2018 | Dec 31, 2018 | $167.14M | +19.9% |
| FY2017 | Dec 31, 2017 | $139.42M | – |
| FY2016 | Dec 31, 2016 | -$7.70M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$51.94M | -185.2% |
| Q1 FY2026 | Mar 31, 2026 | -$34.92M | – |
| Q4 FY2025 | Dec 31, 2025 | $108.54M | +5.5% |
| Q3 FY2025 | Sep 30, 2025 | $106.15M | -15.0% |
| Q2 FY2025 | Jun 30, 2025 | $60.99M | +110.1% |
| Q1 FY2025 | Mar 31, 2025 | -$5.75M | – |
| Q4 FY2024 | Dec 31, 2024 | $102.92M | -18.3% |
| Q3 FY2024 | Sep 30, 2024 | $124.83M | +79.0% |
| Q2 FY2024 | Jun 30, 2024 | $29.03M | – |
| Q1 FY2024 | Mar 31, 2024 | -$13.61M | -110.5% |
| Q4 FY2023 | Dec 31, 2023 | $125.96M | – |
| Q3 FY2023 | Sep 30, 2023 | $69.73M | -6.4% |
| Q2 FY2023 | Jun 30, 2023 | -$23.35M | – |
| Q1 FY2023 | Mar 31, 2023 | $130.02M | +18.7% |
| Q4 FY2022 | Dec 31, 2022 | -$34.76M | -176.0% |
| Q3 FY2022 | Sep 30, 2022 | $74.47M | +3.8% |
| Q2 FY2022 | Jun 30, 2022 | -$130.57M | – |
| Q1 FY2022 | Mar 31, 2022 | $109.55M | -19.7% |
| Q4 FY2021 | Dec 31, 2021 | $45.76M | -40.1% |
| Q3 FY2021 | Sep 30, 2021 | $71.72M | +112.3% |
| Q2 FY2021 | Jun 30, 2021 | -$59.74M | -135.0% |
| Q1 FY2021 | Mar 31, 2021 | $136.35M | +227.3% |
| Q4 FY2020 | Dec 31, 2020 | $76.43M | – |
| Q3 FY2020 | Sep 30, 2020 | $33.78M | -73.4% |
| Q2 FY2020 | Jun 30, 2020 | $170.69M | +1705.7% |
| Q1 FY2020 | Mar 31, 2020 | $41.66M | – |
| Q4 FY2019 | Dec 31, 2019 | -$55.41M | -123.1% |
| Q3 FY2019 | Sep 30, 2019 | $126.88M | +255.8% |
| Q2 FY2019 | Jun 30, 2019 | $9.45M | – |
| Q1 FY2019 | Mar 31, 2019 | -$126.40M | -1778.6% |
| Q4 FY2018 | Dec 31, 2018 | $239.63M | – |
| Q3 FY2018 | Sep 30, 2018 | $35.66M | -38.5% |
| Q2 FY2018 | Jun 30, 2018 | -$115.68M | – |
| Q1 FY2018 | Mar 31, 2018 | $7.53M | – |
| Q4 FY2017 | Dec 31, 2017 | -$24.62M | – |
| Q3 FY2017 | Sep 30, 2017 | $57.97M | – |
See a number that looks wrong?